Extended Data Fig. 3: Characterization of the response of PC9 cells to erlotinib, GNE-069, and GNE-104.
From: Identifying transcriptional programs underlying cancer drug response with TraCe-seq
(a) Heatmap and dendrogram showing survival patterns of 500 different PC9 clones subject to erlotinib (2 µM) or GNE-104 (1 µM) treatment for two months. Clonal abundance was determined by NGS barcode analyses from genomic DNA. Barcode enrichment were highly reproducible within individual treatment and differed between erlotinib and GNE-104 treatments. (b–d) Comparison of the anti-growth effects of erlotinib, GNE-069, and GNE-104 in PC9 cells by (b) clonogenic assay, scale bar, 1 mm, (c) cell counting in triplicates (200 K cells per well in 6-well plates), and (d) Incucyte imaging, scale bar, 200 µm. All three compounds were applied at 1 µM. The experiments were repeated 3 times with similar results. Erlotinib and GNE-069 had comparable activity by all three measures, whereas GNE-104 was less efficacious.
